...
首页> 外文期刊>The journal of clinical investigation >Lack of protease inhibitor resistance following treatment failure— too good to be true?
【24h】

Lack of protease inhibitor resistance following treatment failure— too good to be true?

机译:治疗失败后缺乏对蛋白酶抑制剂的抗药性-太好了吗?

获取原文
           

摘要

A 29-year-old man with recently diagnosed HIV infection and a CD4 cell count of225/mm~(3) began treatment with atazanavir (300 mg), ritonavir (100 mg),emtricitabine (200 mg), and tenofovir (300 mg) daily. For 18 months, he was treatmentadherent and his plasma HIV RNA level was below the limit of detection. He then begana relationship with a new partner, who introduced him to methamphetamines. Hismedication adherence became erratic, and he missed appointments in clinic.Eventually. he was hospitalized for rehabilitation, and he resumed taking hismedications on schedule. Following his discharge, he was found to have a plasma HIVRNA level of 11,400 copies/ml. Genotypic resistance testing revealed only an M184Vmutation associated with emtricitabine resistance. A decision regarding his nexttreatment regimen needs to be made.
机译:一名最近被确诊为HIV感染且CD4细胞计数为225 / mm〜(3)的29岁男性开始使用阿扎那韦(300 mg),利托那韦(100 mg),恩曲他滨(200 mg)和替诺福韦(300 mg)治疗) 日常。 18个月来,他坚持治疗,血浆HIV RNA水平低于检出限。然后,他与一个新伴侣开始了恋爱关系,并向他介绍了甲基苯丙胺。他对药物的依从性变得不稳定,他错过了在诊所的约会。最终。他因康复而住院,并按时恢复服药。出院后,他的血浆HIVRNA水平为11,400拷贝/ ml。基因型抗药性测试仅显示与恩曲他滨抗药性相关的M184V突变。必须就他的下一个治疗方案做出决定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号